Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| RB Rejuvenate BioCompany profile Develops gene therapies for age-related and chronic diseases in animals and humans Develops gene therapies for age-related and chronic diseases in animals and humans | $6M | StrategicUndisclosed | Biotech | United States | Investors | |
| CT City TherapeuticsCompany profile City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas. City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas. | $99.5M | Series B | Biotech | United States | Investors | |
| OP Develops RNAi therapeutics for various diseases | ₩110B | StrategicUndisclosed | Biotech | South Korea | Investors | |
| ND New Dawn BioCompany profile Grows cultured wood from tree stem cells in bioreactors, eliminating the need for logging Grows cultured wood from tree stem cells in bioreactors, eliminating the need for logging | €2.1M | Pre-SeedPre-seed | Biotech, Climate tech | Netherlands | Investors | |
| AB ARTAN BioCompany profile Develops mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions Develops mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions | $200K | Seed | Biotech | United States | Investors | |
| GT Goldenrod TherapeuticsCompany profile Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways | $6.5M | Seed | Biotech | United States | Investors | |
| S ScispotCompany profile Provides an AI-native operating layer for life sciences labs to automate work and track samples Provides an AI-native operating layer for life sciences labs to automate work and track samples | $8M | Series A | Biotech | Canada | Investors | |
| I IngenixCompany profile Builds AI architecture fusing biological data modalities to accelerate pharma and biotech drug development Builds AI architecture fusing biological data modalities to accelerate pharma and biotech drug development | €13M | Seed+Seed | Biotech | Poland | Investors | |
 ApohaCompany profile Apoha measures molecular behavior for pharmaceutical, food and materials research. Apoha measures molecular behavior for pharmaceutical, food and materials research. | Undisclosed | Series A | Biotech, Industrial tech | United Kingdom | Investors | |
| IH Ilant HealthCompany profile Delivers AI-enabled, value-based obesity and cardiometabolic care to employers and health plans Delivers AI-enabled, value-based obesity and cardiometabolic care to employers and health plans | $15M | Series A | Biotech, Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.